EswatiniMed challenges competition ruling in High Court
The medical aid fund is seeking to set aside a decision that its activities fall under the Competition Act after the commission dismissed its jurisdictional objection.

EswatiniMed has approached the High Court to review and set aside a ruling by the Eswatini Competition Commission. The fund is challenging the decision that its activities fall within the scope of the Competition Act. The matter is scheduled to be heard on November 20 at 9:30am.
The commission previously delivered a ruling on July 31, 2026, dismissing EswatiniMed’s preliminary points of law. The commission held that the fund’s medical aid activities were subject to competition law despite its not-for-profit status, reasoning that providing medical aid in exchange for contributions constitutes economic activity.
The investigation follows complaints from Paramed Laboratories and the Eswatini Private Doctors Association (EPDA). Paramed Laboratories alleged that EswatiniMed refused to issue practice numbers to certain providers and revoked numbers previously allocated to some practitioners and facilities. The EPDA accused the fund of using a non-price predatory strategy to disadvantage and potentially eliminate competitors of healthcare providers associated with the fund.
An investigation report issued by the commission’s Secretariat on February 10, 2025, concluded that EswatiniMed held a dominant position in the healthcare cover market and engaged in anti-competitive trade practices. The Secretariat recommended an administrative penalty equivalent to 4.398 per cent of the fund’s total turnover.
The July 31 ruling referred the matter to the second stage to determine the substantive allegations of anti-competitive conduct. The ruling did not finally establish that EswatiniMed had engaged in anti-competitive conduct.
Key facts
- EswatiniMed is challenging the commission's ruling in the High Court on November 20 at 9:30am.
- The commission ruled that EswatiniMed's medical aid activities are subject to the Competition Act No. 8 of 2007.
- The Secretariat recommended an administrative penalty of 4.398 per cent of the fund's total turnover.
Three perspectives
Neutral
EswatiniMed is seeking a High Court review of a commission ruling that its activities fall under the Competition Act.
Positive
The Eswatini Competition Commission is investigating allegations of anti-competitive practices to ensure fair market competition.
Negative
Paramed Laboratories and the EPDA allege that EswatiniMed used predatory strategies to frustrate and potentially eliminate healthcare competitors.
Your week in news, every Wednesday
The biggest stories of the week for your edition, in your inbox every Wednesday morning, your time. Free, and you can unsubscribe at any time.